Details for New Drug Application (NDA): 061999
✉ Email this page to a colleague
NDA 061999 describes NALLPEN, which is a drug marketed by Glaxosmithkline and Baxter Hlthcare and is included in three NDAs. Additional details are available on the NALLPEN profile page.
The generic ingredient in NALLPEN is nafcillin sodium. There are eleven drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the nafcillin sodium profile page.
The generic ingredient in NALLPEN is nafcillin sodium. There are eleven drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the nafcillin sodium profile page.
Summary for 061999
| Tradename: | NALLPEN |
| Applicant: | Glaxosmithkline |
| Ingredient: | nafcillin sodium |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 061999
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 500MG BASE/VIAL | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1GM BASE/VIAL | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 2GM BASE/VIAL | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
